The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
A new company will develop “next-generation mRNA” projects, amid another mRNA setback.
Persevera is a bust, but Roche hasn’t given up on the front line.
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
The company pays $2.5bn for Day One and its approved drug Ojemda.
Ono's antisense therapy is to begin its first pivotal trial.
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
